Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fibrous sheath-interacting protein 1 (FSIP1)
- Target
- FSIP1
- Molecular classification
- Other (structural protein), Cytoskeletal protein, Fibrous sheath component
01
Overview
Fibrous sheath-interacting protein 1 (FSIP1) is a structural protein that forms part of the fibrous sheath in sperm flagella, essential for sperm motility and integrity. In cancer cells, FSIP1 is aberrantly overexpressed where it can stabilize microtubule networks, interact with cancer/testis antigens, and promote cell proliferation and metastatic features. Elevated FSIP1 levels are strongly correlated with poor outcomes in breast and non-small cell lung cancer patients, and FSIP1 mediates chemoresistance by modulating the stability of multidrug resistance protein 1 (MRP1). FSIP1 is under investigation as both a pathological biomarker and as a therapeutic target, particularly for combating drug resistance and progression in certain cancers.
- Other names
- FSIP1Fibrous sheath interacting protein 1FLJ35989HGNC:21674NCBI Gene:161835UniProtKB: Q8NA03
02
Mechanism of action
Drugs targeting FSIP1 may sensitize tumor cells to chemotherapeutic agents by reducing FSIP1 expression or function, thereby increasing cellular drug accumulation and decreasing resistance (e.g., docetaxel sensitivity improves upon FSIP1 knockout)
03
Biological functions
Sperm cell development and function (flagellar structure)Microtubule organizationCell mitosis and proliferationCancer progression (Breast, NSCLC)
04
Disease associations
Cancer (Breast cancer, Non-small cell lung cancer)Syndromic X-linked intellectual disability type 10
05
Safety considerations
Unknown direct safety concerns; therapeutic targeting must consider FSIP1’s role in normal sperm cell development and cellular homeostasisOff-target effects in tissues expressing FSIP1 in non-cancer contexts require investigation
06
Interacting drugs
Docetaxel
1 more in the full profile.
07
Biomarkers
FSIP1 expression is a prognostic biomarker for poor survival in breast and non-small cell lung cancersIt may also enhance prognostic accuracy when combined with the TNM staging system in NSCLC
Beyond the preview
Go deeper on Fibrous sheath-interacting protein 1 (FSIP1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fibrous sheath-interacting protein 1 (FSIP1).